Roche Says Kadcyla Fails To Better Herceptin In First-Line Breast Cancer
This article was originally published in The Pink Sheet Daily
Sales estimates for Roche’s Kadcyla will be cut sharply after news the MARIANNE study didn’t show the antibody-drug conjugate performing better than Herceptin in treating first-line breast cancer.
You may also be interested in...
Roche plans to file I.V. anti-CD20 antibody ocrelizumab in multiple sclerosis early in 2016, after disclosing that the drug met endpoints in two Phase III studies against Merck Serono’s Rebif.
The big pharma has renewed interest in the anti-amyloid beta antibody – which failed a large Phase III trial - after Biogen released positive early data on a similar rival compound.
Roche’s key HER2 breast cancer franchise boasted a stellar sales performance in the first-quarter – rising 27% in the U.S. alone – and the rest of the cancer business followed suit. But, the loss of schizophrenia candidate bitopertin casts a shadow on the firm’s plans for neuroscience.